EGFR and ovarian carcinoma: Downregulation of HNF1β could contribute to drug resistance in ovarian cancer and that HNF1β may perform its drug resistance-related functions through four pathways including ErbB signaling, focal adhesion, apoptosis and p53 signaling [34].